EUVIMEDEUVIMED entdecken
Crossref

Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target

Gisele Lopes Cavalcante, Lívia Pimenta Bonifacio, Jéssica Maria Sanches-Lopes, Fernanda Guioti Puga, Felipe Santos de Carvalho, Fernando Bellissimo-Rodrigues, Jose Eduardo Tanus-Santos iD

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Gisele Lopes Cavalcante und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-1, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID‐19 is a devastating disease and imbalanced matrix metalloproteinase (MMP) activity may contribute to its pathophysiology. This exploratory study examined whether increased circulating concentrations of MMP‐2 and MMP‐9, and their endogenous inhibitors, the tissue inhibitors of MMP (TIMP)‐1, TIMP‐2, TIMP‐3 and TIMP‐4 are persistently found in patients 2 weeks after their recovery from severe or critical COVID‐19 as compared with those in healthy controls. Subjects who had severe ( n = 26) or critical ( n = 25) PCR‐confirmed COVID‐19 and healthy controls ( n = 21) had blood samples drawn 2 weeks after recovery and serum MMP‐2, MMP‐9, TIMP‐1, TIMP‐2, TIMP‐3 and TIMP‐4 were determined using two Human Luminex® Discovery Assays. Circulating MMP activity was also determined by gel zymography. Patients who had severe or critical COVID‐19 had increased circulating MMP‐9 and MMP‐2 concentrations, with increased MMP‐9/TIMP‐1 and MMP‐2/TIMP‐2 ratios indicating increased MMP activity, confirmed by gel zymography (all p < 0.05). Higher circulating MMP‐9 (but not MMP‐2) concentrations were found in critical versus severe COVID‐19 ( p < 0.05). We found increased circulating MMP‐9 and MMP‐2 concentrations and activity many days after recovery from the acute disease, with MMP‐9 levels associated with disease severity. These biochemical alterations suggest that MMP‐2 and MMP‐9 may be important pharmacological targets in COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Inhibitor of Metalloproteinase-1COVID-19HumansTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-3Matrix Metalloproteinase 9Matrix Metalloproteinase 2Severity of Illness Index

Stichwörter der Autor:innen

COVID‐19TIMPsmatrix metalloproteinases

Substanzen

Tissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-3Matrix Metalloproteinase 9Matrix Metalloproteinase 2

Autor:innen und Institutionen

  • Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
  • Department of Social Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil.
  • Department of Medicine, Federal University of São Carlos, São Carlos, SP, Brazil.

ORCID-Profile: Jose Eduardo Tanus-Santos

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Cavalcante, G. L., Bonifacio, L. P., Sanches-Lopes, J. M., Puga, F. G., de Carvalho, F. S., Bellissimo-Rodrigues, F., & Tanus-Santos, J. E. (2024). Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14001

Vancouver

Cavalcante GL, Bonifacio LP, Sanches-Lopes JM, Puga FG, de Carvalho FS, Bellissimo-Rodrigues F, et al. Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14001

BibTeX
@article{Cavalcante2024,
  author = {Cavalcante, Gisele Lopes and Bonifacio, Lívia Pimenta and Sanches-Lopes, Jéssica Maria and Puga, Fernanda Guioti and de Carvalho, Felipe Santos and Bellissimo-Rodrigues, Fernando and Tanus-Santos, Jose Eduardo},
  title = {Matrix metalloproteinases are associated with severity of disease among COVID‐19 patients: A possible pharmacological target},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14001}
}
Kostenlos starten →